Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-701,324 is a an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor.
Sold with the permission of Merck Sharp and Dohme Ltd.
M. Wt | 363.8 |
Formula | C21H14ClNO3 |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 142326-59-8 |
PubChem ID | 54682505 |
InChI Key | FLVRDMUHUXVRET-UHFFFAOYSA-N |
Smiles | OC1=C(C(=O)NC2=CC(Cl)=CC=C12)C1=CC=CC(OC2=CC=CC=C2)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 100 |
The following data is based on the product molecular weight 363.8. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.75 mL | 13.74 mL | 27.49 mL |
5 mM | 0.55 mL | 2.75 mL | 5.5 mL |
10 mM | 0.27 mL | 1.37 mL | 2.75 mL |
50 mM | 0.05 mL | 0.27 mL | 0.55 mL |
References are publications that support the biological activity of the product.
Bristow et al (1996) The atypical neuroleptic profile of the glycine/N-MthD.-aspartate receptor antagonist, L-701,324 in rodents. J.Pharmacol.Exp.Ther. 277 578 PMID: 8627534
Bristow et al (1996) Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-MthD.-aspartate receptor complex. J.Pharmacol.Exp.Ther. 279 492 PMID: 8930150
Kulagowski et al (1994) 3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. J.Med.Chem. 37 1402 PMID: 8182696
Obrenovitch and Zilkha (1996) Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-MthD.-aspartate receptor complex. Br.J.Pharmacol. 117 931 PMID: 8851513
If you know of a relevant reference for L-701,324, please let us know.
Keywords: L-701,324, L-701,324 supplier, NMDA, antagonist, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, L701324, 0907, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for L-701,324 include:
Bäckström and Hyytiä (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31 778 PMID: 16123768
Do you know of a great paper that uses L-701,324 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review L-701,324 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.